$BPTH
BIO-PATH HOLDINGS, INC.

2023 Q4 Form 10-Q Financial Statement

#000155837023019024 Filed on November 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $757.0K $980.0K
YoY Change -32.59% -17.85%
% of Gross Profit
Research & Development $2.276M $2.292M
YoY Change -20.5% -2.59%
% of Gross Profit
Depreciation & Amortization $16.00K $30.00K
YoY Change -30.43% 36.36%
% of Gross Profit
Operating Expenses $3.033M $3.276M
YoY Change -23.91% -7.61%
Operating Profit -$3.276M
YoY Change -7.61%
Interest Expense $4.000K $10.00K
YoY Change -80.0% -9.09%
% of Operating Profit
Other Income/Expense, Net -$343.0K $77.00K
YoY Change 600.0%
Pretax Income -$3.372M -$3.200M
YoY Change -14.98% -9.48%
Income Tax
% Of Pretax Income
Net Earnings -$3.372M -$3.199M
YoY Change -14.98% -9.5%
Net Earnings / Revenue
Basic Earnings Per Share -$0.32
Diluted Earnings Per Share -$5.51 -$0.32
COMMON SHARES
Basic Shares Outstanding 12.35M 11.46M
Diluted Shares Outstanding 10.05M

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.052M $2.350M
YoY Change -89.87% -82.78%
Cash & Equivalents $1.052M $2.352M
Short-Term Investments
Other Short-Term Assets $1.990M $1.800M
YoY Change 21.05% -15.89%
Inventory
Prepaid Expenses $632.0K $632.0K
Receivables
Other Receivables
Total Short-Term Assets $3.042M $4.802M
YoY Change -80.52% -73.52%
LONG-TERM ASSETS
Property, Plant & Equipment $178.0K $92.00K
YoY Change 12.66% -49.17%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $178.0K $219.0K
YoY Change -50.0% -45.52%
TOTAL ASSETS
Total Short-Term Assets $3.042M $4.802M
Total Long-Term Assets $178.0K $219.0K
Total Assets $3.220M $5.021M
YoY Change -79.84% -72.92%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $57.00K $300.0K
YoY Change -91.45% -70.0%
Accrued Expenses $1.449M $1.000M
YoY Change 61.0% -9.09%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.906M $1.357M
YoY Change 13.18% -38.35%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $873.0K $1.140M
YoY Change 672.57% 708.51%
Total Long-Term Liabilities $873.0K $1.140M
YoY Change 672.57% 708.51%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.906M $1.357M
Total Long-Term Liabilities $873.0K $1.140M
Total Liabilities $2.779M $2.496M
YoY Change 54.65% 6.58%
SHAREHOLDERS EQUITY
Retained Earnings -$107.6M -$104.2M
YoY Change 17.6% 19.04%
Common Stock $1.000K $11.00K
YoY Change -87.5% 57.14%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $441.0K $2.500M
YoY Change
Total Liabilities & Shareholders Equity $3.220M $5.021M
YoY Change -79.84% -72.92%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$3.372M -$3.199M
YoY Change -14.98% -9.5%
Depreciation, Depletion And Amortization $16.00K $30.00K
YoY Change -30.43% 36.36%
Cash From Operating Activities -$1.814M -$2.780M
YoY Change -63.72% -17.61%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 514.0K 1.690M
YoY Change -70.36%
NET CHANGE
Cash From Operating Activities -1.814M -2.780M
Cash From Investing Activities 0.000
Cash From Financing Activities 514.0K 1.690M
Net Change In Cash -1.300M -1.090M
YoY Change -60.2% -67.69%
FREE CASH FLOW
Cash From Operating Activities -$1.814M -$2.780M
Capital Expenditures $0.00
Free Cash Flow -$2.780M
YoY Change -17.61%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
12352664
CY2023Q3 us-gaap Cash
Cash
2352000
CY2022Q4 us-gaap Cash
Cash
10384000
CY2023Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
632000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
3587000
CY2023Q3 us-gaap Other Assets Current
OtherAssetsCurrent
1818000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1644000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
4802000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
15615000
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1120000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1120000
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1028000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
962000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
92000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
158000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
127000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
198000
CY2023Q3 us-gaap Assets
Assets
5021000
CY2022Q4 us-gaap Assets
Assets
15971000
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.32
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.49
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.47
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.38
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10053000
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7160000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8665000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7160000
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7960000
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11460000
dei Entity Registrant Name
EntityRegistrantName
BIO-PATH HOLDINGS INC
dei Entity Central Index Key
EntityCentralIndexKey
0001133818
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36333
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
87-0652870
dei Entity Address Address Line1
EntityAddressAddressLine1
4710 Bellaire Boulevard, Suite 210
dei Entity Address City Or Town
EntityAddressCityOrTown
Bellaire
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77401
dei City Area Code
CityAreaCode
832
dei Local Phone Number
LocalPhoneNumber
742-1357
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
BPTH
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
277000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
667000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
964000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
909000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
116000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
108000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1357000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1684000
CY2023Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
1114000
CY2022Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
0
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
25000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
113000
CY2023Q3 us-gaap Liabilities
Liabilities
2496000
CY2022Q4 us-gaap Liabilities
Liabilities
1797000
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11460000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7960000
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
11000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
8000
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
106749000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
105695000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-104235000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-91529000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
2525000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
14174000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5021000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15971000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2292000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2353000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9332000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6302000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
984000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1193000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3478000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3613000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
3276000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
3546000
us-gaap Operating Expenses
OperatingExpenses
12810000
us-gaap Operating Expenses
OperatingExpenses
9915000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3276000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3546000
us-gaap Operating Income Loss
OperatingIncomeLoss
-12810000
us-gaap Operating Income Loss
OperatingIncomeLoss
-9915000
CY2023Q3 bpth Income Recognized From Fair Value Adjustment Of Warrants
IncomeRecognizedFromFairValueAdjustmentOfWarrants
72000
bpth Income Recognized From Fair Value Adjustment Of Warrants
IncomeRecognizedFromFairValueAdjustmentOfWarrants
72000
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
5000
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
11000
us-gaap Investment Income Interest
InvestmentIncomeInterest
32000
us-gaap Investment Income Interest
InvestmentIncomeInterest
13000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
77000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
11000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
104000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
13000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-3199000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-3535000
us-gaap Net Income Loss
NetIncomeLoss
-12706000
us-gaap Net Income Loss
NetIncomeLoss
-9902000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.32
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.49
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.47
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.38
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10053000
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7160000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8665000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7160000
us-gaap Net Income Loss
NetIncomeLoss
-12706000
us-gaap Net Income Loss
NetIncomeLoss
-9902000
us-gaap Share Based Compensation
ShareBasedCompensation
554000
us-gaap Share Based Compensation
ShareBasedCompensation
642000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
71000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
67000
us-gaap Depreciation
Depreciation
66000
us-gaap Depreciation
Depreciation
65000
bpth Income Recognized From Fair Value Adjustment Of Warrants
IncomeRecognizedFromFairValueAdjustmentOfWarrants
72000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-2955000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
1824000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
174000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
297000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-335000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1220000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-80000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-74000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9721000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10103000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
21000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-21000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1689000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1689000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-8032000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-10124000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10384000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
23774000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2352000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13650000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
85000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
19520000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
212000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-3535000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
16197000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
5043000
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
503000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
178000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-3199000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
2525000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
25457000
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
642000
us-gaap Net Income Loss
NetIncomeLoss
-9902000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
16197000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
14174000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
503000
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
554000
us-gaap Net Income Loss
NetIncomeLoss
-12706000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
2525000
CY2023Q3 us-gaap Cash
Cash
2400000
CY2023Q3 us-gaap Other Assets Current
OtherAssetsCurrent
1800000
CY2023Q3 us-gaap Prepaid Advertising
PrepaidAdvertising
1300000
CY2023Q3 us-gaap Prepaid Insurance
PrepaidInsurance
400000
CY2023Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
100000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1600000
CY2022Q4 us-gaap Prepaid Advertising
PrepaidAdvertising
1300000
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
300000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
300000
CY2023Q3 bpth Legal And Patent Fees Payable
LegalAndPatentFeesPayable
200000
CY2023Q3 bpth Clinical Trial Expenses Payable
ClinicalTrialExpensesPayable
100000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
700000
CY2022Q4 bpth Drug Manufacturing Development And Testing Expenses Payable
DrugManufacturingDevelopmentAndTestingExpensesPayable
600000
CY2022Q4 bpth Legal And Patent Fees Payable
LegalAndPatentFeesPayable
100000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1000000.0
CY2023Q3 us-gaap Accrued Vacation Current
AccruedVacationCurrent
400000
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
200000
CY2023Q3 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
200000
CY2023Q3 us-gaap Accrued Advertising Current
AccruedAdvertisingCurrent
100000
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
100000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
900000
CY2022Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
400000
CY2022Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
200000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
100000
CY2022Q4 us-gaap Accounts Payable And Other Accrued Liabilities
AccountsPayableAndOtherAccruedLiabilities
100000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
100000
CY2023Q3 bpth Net Period Change In Fair Value Of Warrant Liability
NetPeriodChangeInFairValueOfWarrantLiability
100000
CY2023Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
1114000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
2500000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
14200000
CY2023Q3 us-gaap Other Commitment Due In Next Twelve Months
OtherCommitmentDueInNextTwelveMonths
1000000.0

Files In Submission

Name View Source Status
0001558370-23-019024-index-headers.html Edgar Link pending
0001558370-23-019024-index.html Edgar Link pending
0001558370-23-019024.txt Edgar Link pending
0001558370-23-019024-xbrl.zip Edgar Link pending
bpth-20230930.xsd Edgar Link pending
bpth-20230930x10q.htm Edgar Link pending
bpth-20230930xex31.htm Edgar Link pending
bpth-20230930x10q_htm.xml Edgar Link completed
bpth-20230930xex32.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
bpth-20230930_cal.xml Edgar Link unprocessable
bpth-20230930_lab.xml Edgar Link unprocessable
bpth-20230930_def.xml Edgar Link unprocessable
bpth-20230930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable